In 2022, Evorpacept, a fusion protein containing two engineered high-affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin was designed to promote the phagocytosis of tumor cells and was tested in combination with VEN and AZA in R/R AML or ND HR AML. This evidence concerns the gene SIRPA and acute myeloid leukemia.